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Of the numerous diseases afflic­
ting mankind, those rendering 
their victims suddenly intensive 
care patients have been, besi­
des cancer, perhaps one of the 
greatest challenges for biome­
dical research in the last two 
decadea Examples of such dis­
eases are the acute respiratory 
distress syndrome (ARDS) 
and/or septicemia due to exten­
sive selective operations or 
accidents. Recent develop­
ments have considerably in­
creased our understanding of 
the etiology of such inflam­
matory processes and, conse­
quently, enabled the develop­
ment of chemotherapeutic 
agents for these and other 
related ailments1. 
Aspects of inflammation 
The inflammatory response of 
the organism to various insults 
(mechanical trauma, operation, 
infection) is characterized by the 
activation as well as complex in­
teractions of humoral and 
cellular systems1* ζ · 3 ( f ig. 1)* 
This includes the turnover of 
proenzymes of the clotting, fi­
brinolytic, complement and kal-
likrein/kinin cascades to active 
proteinases (thrombin, plasrnin, 
complement esterases, plasma 
kallikrein etc.) which in turn are 
able to produce further potent 
inflammatory mediators like, for 
example, permeability increas­
ing fibrin monomers and fibrin 
split products, anaphylactic 
complement-derived factors 
C3a, C4a and C5a, or vasoac­
tive kinine, prostaglandins and 
leukotrienes. Most of these 
compounds have strong stimu­
latory effects on the primary in­
flammatory defense cells, the 
polymorphonuclear (PMN) gra­
nulocytes and monocytes/ 
macrophages, After having 
been attracted to the inflam­
matory focus by the chemotac-
tic mediators or toxins from 
bacteria as well as leukocytic 
products themselves (tumor 
necrosis factor, interfeukins), the 
main task of the phagocytes is 
the uptake and inactivation of in­
vasive microorganisms and 
metabolic or degraded prod­
ucts via the process of 
phagocytosis (Fig. 2). 
During incorporation of such 
particles into the eel! mem-
brane-derived phagosome, this 
digestion vacuole fuses with 
lysosomes, i.e. membrane-
coated organelles containing 
various destructive proteinases 
(elastase, cathepsin G t cathep-
sin Β eta) and hydrolases. In ad­
dition to these digestive en­
zymes, the phagocytotic pro­
cess is amplified by reactive 
oxygen species produced by 
the respiratory burst and the 
catalytic action of the lysosomal 
proteins myeloperoxidase and 
lactoferrin, 
Although these substances are 
indispensable for an effective in­
tracellular digestion, they bear a 
tremendous pathogenic po­
tential if released extracellularly 
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Despite the already high stan­
dard in intensive-eare-treat-
ment it is obvious that severe 
acute inflammatory processes 
like acute respiratory distress 
syndrome and septicemia still 
deserve a further improvement 
in therapeutic regimens. The 
well-timed application of po­
tent elastase inhibitors seems 
to be a promising tool in 
preventing or at least 
ameliorating sequelae of 
massive inflammatory organ 
failure. Production of such 
therapeutic drugs by recombi­
nant DNA4eehniques may be 
the method of choice for the 
near future 
I l l l l jllliii F\g. 1: 
Schematic depiction of the 
mutual activation of 
humoral and cellular 
systems and the release of 
potent mediators owng 
acute inflammation 
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Fig, 2: 
Diagram of the events 
associated with the 
phagocytosis of PMN ceils. 
56 
in higher amounts before the 
phagolysomes have been clos­
e d By this means, vital struc­
tural elements {basal mem­
branes, cell receptors, fibronec-
tin, elastin, collagen, pro­
teoglycans eta) as well as 
humoral factors including 
plasma proteins in close vicinity 
to the phagocytizing ceils may 
be impaired unless the lyso­
somal proteolytic enzymes and 
oxidative phagocyte-derived 
products are inactivated by 
physiological regulatory pro­
teinase inhibitors. 
Functional aspects 
Of the lysosomal proteinases 
studied so fan the neutral serine 
proteinase elastase from PMN 
granulocytes has attracted most 
interest because of its occur­
rence in high quantities ( 3 -5 
/*g/1(F PMN cells) within the 
granules and its low substrate 
specificity2, The latter enables 
elastase to degrade in» 
tmoellularly nearly alt species of 
phagocytized foreign proteins, 
but also to initiate the break­
down of the body's own vital 
tissues if released M o the ex* 
tracefluiar milieu, in Ihm respect 
the so-called shock organs are 
especially endangered, be­
cause PMN granulocytes are 
primarily sequestered and ac­
tivated in the capillaries of those 
tissues during severe inflam­
matory processes. Conse­
quently, we have been able to 
show a clear correlation bet­
ween the amount of elastase 
released extracelfularly and the 
severity of organ failure or sep­
ticemia in several clinical studies 
wer the last few years 4 - " . 
In addition, liberated elastase 
seems to play also a fatal rote 
with systemic consequences for 
hemostasis by proteolytic inac-
tivation of the plasma pro* 
teinase inhibitors antithrombin 
III, a r pfasmin inhibitor, and 
CMnactivator, the principal an* 
tagonists of active proteinases 
of the blood cascade systems7 
8 Ά As shown recently, this pro­
teolytic degradation may be 
enhanced by oxidative 
dehaturatfon in the surroun­
dings of phagocytizing ceils 1 0. 
Contrasting these pathological 
effects of high amounts of 
elastase released extracellularly 
during severe inflammation, 
small concentrations of this en­
zyme either membrane-
associated or in close vicinity to 
the phagocyte may also be of 
physiologic relevance. Secre­
tion of PMN elastase upon 
chemotactic activation could be 
a prerequisite for migration of 
granulocytes through connec­
tive tissues11 towards the inflam­
matory focus, where the cells 
have to eliminate the deterio­
rating stimuli, To balance the 
positive and negative effects of 
elastase, a delicate control of 
the enzyme by convenient pro­
teinase inhibitors is obviously 
necessary. 
Elastase inhibitors 
Up to date, four different pro­
teinase inhibitors of human 
origin have been described, 
which may be involved in the 
in vivo regulation of PMN 
elastase in plasma and other 
body fluids and tissues (Table 
1)11 « α ΓProteinase inhibitor 
to PI) plays the major role in 
this process, not only because 
of its highest molar concentra­
tion in plasma (and presumably 
also in the extravascular en­
vironments), but also due to the 
rapid inactivation (tl/2 » 0.6 
msec) of its major target en­
zyme, the PMN elastase 
In contrast, a rmacroglobulin 
(ct2M) ~* a potent inhibitor of all 
classes of proteinases (serine, 
cysteine, metallo, and carboxyl 
proteinases) - is a slow-reac­
ting elastase inhibitor with a 
much lower molar concentra­
tion in plasma compared to 
PI, Because of its high M r 
(725,000 D) a 2 M is normally 
restricted to the circulation. It is 
found in other body fluids (eg, 
bronchial and peritoneal secre­
tions) in relevant amounts only 
when the permeability barrier is 
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already disturbed by the action 
of inflammatory mediators13 H . 
Moreover, o?2M-eiastase com­
plexes retain proteolytic activity 
(at least against small 
substrates) and are eliminated 
slowly from local body fluids. 
Therefore, they may still con­
tribute to proteolytic degrada­
tion in such inflammatory en­
vironments. Taking into account 
all these facts, a2M is not usual­
ly considered to be an efficient 
PMN eiastase inhibitor in vivo. 
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Table 1: 
Eiastase Inhibitors oi 
Human Origin 
inhibitory aciive component in mucous secretions 
Inter-a-trypsin inhibitor (ITI), a 
complex of three different pro­
tein species 1 5, shares physiolo­
gical properties with a 2 M in so 
far as the low molecular mass 
inhibitory portion of the complex 
shows a small molar concentra­
tion in plasma and a slow 
eiastase inactivating capa­
bility16. Unlike a 2 M, however, 
this low molecular mass in­
hibitory part (M, 30,000) in­
creases significantly in the 
acute phase state and may 
reach local inflammatory sites in 
amounts sufficient to act as a 
relevant eiastase inactivator. 
Whereas the three eiastase an­
tagonists are primarily produc­
ed and secreted into the circula­
tion by the liver, the mucus pro-
teinase inhibitor (MPI) is a main 
inhibitory component of local 
mucous secretions from various 
tissues17. MPI causes rapid in­
hibition of the neutral PMN pro« 
teinases, eiastase and cathep-
sin G, if released from activated 
cells in the nose, upper airways, 
cervix, and seminal plasma, It 
represents together with a , Pi 
the main antiprotease shield of 
the upper airways (MPI > o^PI) 
and the lung (a, PI > MPI). 
Although a , PI and MPI differ 
significantly concerning their 
molecular mass they have 
several interesting properties in 
common (Table 1). As potent 
eiastase inhibitors their P, - P ^ 
reactive site contains methio­
nine (Met-Ser in a ! PI and Leu-
Met in MPI), an amino acid 
residue, which can easily be ox­
idized by phagocyte oxygen 
species, Such an oxidation 
slows down dramatically the in­
hibition rate of eiastase as well 
as the stability of the elastase/ίη-
hibitor complexes17- 1 S, Hence, 
replacement of the oxidized in­
hibitor may occur by a substrate 
with higher affinity to eiastase, 
for example lung elastin, which 
can thus be degraded by the 
eniyme without restraint. Slow 
inhibition by the oxidized in­
hibitor enables the destruction 
of numerous proteins until the 
eiastase activity is eventually 
abolished. 
In addition, both eiastase an­
tagonists can be inactivated by 
cysteine and metallo pro­
teinases escaping from ac­
tivated macrophages as well as 
by metallo enzymes from dif­
ferent bacteria11. Thus, during 
severe infectious diseases a t PI 
and MPI may rapidly lose their 
inhibitory function at least in 
local inflamed areas. On the one 
hand, this would enable an un­
controlled destructive eiastase 
action leading to the develop-
ment of multiple organ failure. 
On the other hand, granulocyte 
migration through elastin 
matrices might be favoured by 
inactivation of the eiastase in­
hibitors in close vicinity to the 
stimulated cells11, 
Therefore, the following points 
should be considered in view of 
the development of therapeuti-
cally useful eiastase inhibitors 
as potential antiinflammatory 
drugs in acute diseases like 
ARDS or septicemia11: 
• The inhibitor should have 
a medium molecular mass 
(10,000-55,000 D) to ensure 
easy diffusion into the tissues 
but also a half-life time which is 
long enough to establish a suffi­
ciently high inhibitory potential 
within the vascular system and 
locally, as well. 
• The inhibitor should be 
negatively charged to minimize 
its concentration around the 
outer neutrophil cell membrane, 
Thereby its uptake by neutro­
phils and its interference with 
the intracellular protein break- 57 
Neutrophil Eiastase 
We only can characterize sep­
ticemia by its clinical ap­
pearance, without finding a 
satisfying pathogenetic defini­
tion of the process, it is widely 
accepted that sepsis is asso­
ciated with dysfunction or failure 
of the immune system and with 
microcirculatory disturbances, 
and that sepsis is a mediator 
disease. But our knowledge 
about the exact trigger events 
and interactions, responsible for 
the breakdown of regulating 
and compensating mecha­
nisms ending up in the 
disastrous multi organ failure is 
still incomplete. We still lack the 
all-important parameter for the 
clinical assessment of septic pa­
tients. However, the determina­
tion of elastase can provide 
sorne useful clinical information 
(Table 1). 
The elastase level can help to 
differentiate between shock due 
to a cardiac cause or pul­
monary embolism and a septic 
complication. This differential 
diagnosis is often difficult par­
ticularly in older-age intensive 
care patients, and has substan­
tial impact on the therapeutic 
consequences. Moreover, the 
elastase level has been shown 
to be of value in the estimation 
of the prognosis of septic pa­
tients in internal medicine, ab­
dominal surgery and trau­
matology Since in the single 
patient not so much a high initial 
elastase value, but a delayed 
and incomplete decrease is a 
sign of bad prognosis, serial 
determinations during the 
course are advisable 
For improving therapy in septic 
shock a major consideration is 
the use of inhibitors, and at the 
present stage, the best choice 
are the physiologic inhibitors, 
An important inhibitor in the 
physiologic control of coagula­
tion is antithrombin III, The 
Table 1: 
Plasma levels (mean values 
± S£M) of neutrophil 
elastase and thrombin-
antrthrombtn If J (TAT) com­
plexes in various diseases 
Elastase levels mm ummmmd by PNMiJas tase IUBA: 'ihe standardization has bmn changed m the 
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TAT te*®4* w m * d e t e r m i n e by BnzyQrmf* T A T E U S A \ 
Seite Λ , Η Egbfing, D e p t of Hwm*W a n d O n c o k ^ y , t n » m * * M e d i a l Cftmer, Vtw&m mmg 
substitution of antithrombin 
has been shown to be effective 
in the treatment of dissemi­
nated intravascular coagula* 
Won in controlled studies, 
Since in septic shock a distur­
bance of several other me­
diator systems and an enhanc­
ed proteolysis due to enzymes 
such as elastase is present, it 
should be considered to com­
bine the substitution of an­
tithrombin and fresh frozen 
plasma. In an uncontrolled 
study on the treatment of 
coagulation disturbances in 
septic shock we found in those 
patients receiving antithrom­
bin 111 and fresh frozen plasma 
not only a normalization of 
hemostasis and a decrease 
of thrombin-antithrombin-com-
plex (TAT), but also a decrease 
of elastase levels and a better 
survival rate than in septic 
shock patients without 
coagulation disturbance who 
did not receive substitution* 
Thus the assessment of 
elastase levels appears to be 
not only helpful in the clinical 
treatment of patients at risk for 
septic complications, but also 
for monitoring studies aimed 
at the improval of the still 
frustrating therapy of septic 
shock, RS. 
* Satz, β, ei Bl: Eur, J* Haematol, 43; 
22{t9S9). 
δδ. 
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down might be diminished. 
Susceptibility to inactivation by 
oxidants and/or proteolysis by 
lysosomal cysteine proteases 
could additionally prevent such 
undesired effects on the in-
tracellular metabolism. Outside 
the cell, this feature might also 
assure the granulocyte move-
ment towards the infectious 
focus, especially during chronic 
inflammation. 
# The inhibitor should be 
highly specific for neutrophil 
eiastase allowing an effective 
competition with natural protein 
substrates and minimizing 
unspecific toxicity. Concerning 
the latter, the immunotolerance 
to the host should be also as 
high as possible. 
Of the currently discussed and 
also experimentally studied 
eiastase inhibitors just a few 
seem to fulfil such requirements 
- at least in part, 
material compared to the use of 
the original variant, which can 
be consumed also by oxidation. 
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